$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000154908420000041 Filed on October 29, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$2.250M	$2.897M	$3.319M
YoY Change	-39.52%	-12.71%	30.16%
Cost Of Revenue	$890.0K	$1.084M	$1.569M
YoY Change	-52.41%	-30.91%	6.95%
Gross Profit	$1.360M	$1.813M	$1.750M
YoY Change	-26.88%	3.6%	61.59%
Gross Profit Margin	60.44%	62.58%	52.73%
Selling, General & Admin	$3.650M	$3.446M	$4.391M
YoY Change	-11.19%	-21.52%	-25.46%
% of Gross Profit	268.38%	190.07%	250.91%
Research & Development	$710.0K	$599.0K	$1.149M
YoY Change	26.79%	-47.87%	-10.37%
% of Gross Profit	52.21%	33.04%	65.66%
Depreciation & Amortization	$150.0K	$150.0K	$30.00K
YoY Change	-11.76%	400.0%	-89.29%
% of Gross Profit	11.03%	8.27%	1.71%
Operating Expenses	$4.360M	$4.234M	$5.540M
YoY Change	-7.04%	-23.57%	-22.81%
Operating Profit	-$3.000M	-$2.421M	-$3.790M
YoY Change	6.01%	-36.12%	-37.81%
Interest Expense	-$30.00K	$23.00K	$88.00K
YoY Change	-57.14%	-73.86%	-39.31%
% of Operating Profit
Other Income/Expense, Net	-$950.0K	$4.873M	$3.996M
YoY Change	-600.0%	21.95%	-549.49%
Pretax Income	-$3.980M	$2.450M	$210.0K
YoY Change	46.32%	1066.67%	-103.01%
Income Tax
% Of Pretax Income
Net Earnings	-$3.980M	$2.452M	$206.0K
YoY Change	46.32%	1090.29%	-102.95%
Net Earnings / Revenue	-176.89%	84.64%	6.21%
Basic Earnings Per Share		$0.30	$0.04
Diluted Earnings Per Share	-$477.2K	-$0.01	$0.04
COMMON SHARES
Basic Shares Outstanding	8.316M shares	8.236M shares	4.996M shares
Diluted Shares Outstanding		8.379M shares	4.997M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.86M	$14.55M	$8.060M
YoY Change	18.31%	80.52%	-38.0%
Cash & Equivalents	$12.86M	$14.55M	$8.058M
Short-Term Investments
Other Short-Term Assets	$190.0K	$370.0K	$430.0K
YoY Change	-20.83%	-13.95%	-15.69%
Inventory	$1.978M	$2.180M	$3.342M
Prepaid Expenses
Receivables	$3.224M	$4.450M	$5.206M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$18.42M	$21.55M	$17.03M
YoY Change	-2.06%	26.51%	-14.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.172M	$1.033M	$1.723M
YoY Change	-29.27%	-40.05%	-20.6%
Goodwill	$0.00	$0.00	$189.0K
YoY Change	-100.0%	-100.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$320.0K	$118.0K	$172.0K
YoY Change	79.78%	-31.4%	42.15%
Total Long-Term Assets	$2.177M	$1.937M	$3.258M
YoY Change	-29.95%	-40.55%	26.77%
TOTAL ASSETS
Total Short-Term Assets	$18.42M	$21.55M	$17.03M
Total Long-Term Assets	$2.177M	$1.937M	$3.258M
Total Assets	$20.60M	$23.49M	$20.29M
YoY Change	-6.01%	15.74%	-9.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.501M	$1.813M	$1.362M
YoY Change	-21.12%	33.11%	-60.38%
Accrued Expenses	$1.429M	$1.566M	$2.589M
YoY Change	-15.09%	-39.51%	-25.37%
Deferred Revenue	$1.496M	$1.448M	$1.398M
YoY Change	0.27%	3.58%	47.94%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$2.333M
YoY Change	-100.0%	-100.0%	0.0%
Total Short-Term Liabilities	$4.974M	$5.233M	$8.087M
YoY Change	-36.49%	-35.29%	-20.6%
LONG-TERM LIABILITIES
Long-Term Debt	$1.989M	$3.080M	$972.0K
YoY Change	388.7%	216.87%	-69.62%
Other Long-Term Liabilities	$38.00K	$30.00K	$17.00K
YoY Change	-47.22%	76.47%	-37.04%
Total Long-Term Liabilities	$2.027M	$30.00K	$989.0K
YoY Change	323.17%	-96.97%	-69.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.974M	$5.233M	$8.087M
Total Long-Term Liabilities	$2.027M	$30.00K	$989.0K
Total Liabilities	$16.16M	$15.09M	$13.87M
YoY Change	6.91%	8.75%	-17.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$199.1M	-$195.1M	-$180.6M
YoY Change	8.63%	8.07%	8.11%
Common Stock	$8.000K	$8.000K	$75.00K
YoY Change	33.33%	-89.33%	19.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.434M	$8.401M	$6.421M
YoY Change
Total Liabilities & Shareholders Equity	$20.60M	$23.49M	$20.29M
YoY Change	-6.01%	15.74%	-9.5%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$3.980M	$2.452M	$206.0K
YoY Change	46.32%	1090.29%	-102.95%
Depreciation, Depletion And Amortization	$150.0K	$150.0K	$30.00K
YoY Change	-11.76%	400.0%	-89.29%
Cash From Operating Activities	-$1.740M	-$1.270M	-$4.570M
YoY Change	16.78%	-72.21%	8.55%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	2.540M	-600.0K
YoY Change	-100.0%	-523.33%	-117.8%
NET CHANGE
Cash From Operating Activities	-1.740M	-1.270M	-4.570M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	0.000	2.540M	-600.0K
Net Change In Cash	-1.740M	1.270M	-5.170M
YoY Change	-162.59%	-124.56%	501.16%
FREE CASH FLOW
Cash From Operating Activities	-$1.740M	-$1.270M	-$4.570M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$1.740M	-$1.270M	-$4.570M
YoY Change	16.78%	-72.21%	9.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.067
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3M
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2020Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.067
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37854
	dei	Entity Registrant Name EntityRegistrantName	Ekso Bionics Holdings, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-0367049
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1414 Harbour Way South
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1201
	dei	Entity Address City Or Town EntityAddressCityOrTown	Richmond
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94804
	dei	City Area Code CityAreaCode	510
	dei	Local Phone Number LocalPhoneNumber	984-1761
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	EKSO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8316308	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14549000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10872000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	20000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	121000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4450000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5208000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	2180000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	2489000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	370000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	238000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	21549000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	18807000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1033000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1657000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	786000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1084000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	118000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	178000	USD
CY2020Q3	us-gaap	Assets Assets	23486000	USD
CY2019Q4	us-gaap	Assets Assets	21915000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1813000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1903000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1566000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1683000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1448000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1492000	USD
CY2020Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2333000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	406000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	421000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5233000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7832000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1810000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1789000	USD
CY2020Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	3079000	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	407000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	373000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	711000	USD
CY2020Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	4560000	USD
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	4307000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	72000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	15085000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	15118000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8316000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8316000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5795000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5795000	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	203905000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190019000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-385000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195127000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183278000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	8401000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6797000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23486000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21915000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2897000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3319000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6628000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10197000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1084000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1569000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2919000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5288000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	1813000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	1750000	USD
	us-gaap	Gross Profit GrossProfit	3709000	USD
	us-gaap	Gross Profit GrossProfit	4909000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1740000	USD
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2818000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5972000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8666000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	599000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1149000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1762000	USD
CY2019Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	189000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4032000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1706000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1573000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5836000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6011000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	189000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2019Q3	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	244000	USD
	us-gaap	Restructuring Charges RestructuringCharges		USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	4234000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	5540000	USD
	us-gaap	Operating Expenses OperatingExpenses	14003000	USD
	us-gaap	Operating Expenses OperatingExpenses	18709000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2421000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3790000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10294000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13800000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	23000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	88000	USD
	us-gaap	Interest Expense InterestExpense	113000	USD
	us-gaap	Interest Expense InterestExpense	316000	USD
CY2020Q3	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	4476000	USD
CY2019Q3	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	4430000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-1579000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	6045000	USD
CY2020Q3	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
CY2019Q3	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
CY2020Q3	ekso	Warrant Issuance Expense WarrantIssuanceExpense	0	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4873000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3996000	USD
CY2019Q3	ekso	Warrant Issuance Expense WarrantIssuanceExpense	0	USD
	ekso	Warrant Issuance Expense WarrantIssuanceExpense	329000	USD
	ekso	Warrant Issuance Expense WarrantIssuanceExpense	706000	USD
CY2020Q3	ekso	Other Income Expense OtherIncomeExpense	420000	USD
CY2019Q3	ekso	Other Income Expense OtherIncomeExpense	-346000	USD
	ekso	Other Income Expense OtherIncomeExpense	466000	USD
	ekso	Other Income Expense OtherIncomeExpense	-377000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1555000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4389000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	2452000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	206000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11849000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9411000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-415000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	324000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-435000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	366000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2037000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	530000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12284000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9045000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.78
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8236000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4996000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6772000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4684000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8379000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4997000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6829000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4684000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6797000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2534000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	155000	USD
CY2020Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	50000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	587000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	173000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	5228000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-11767000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7082000	USD
CY2020Q2	ekso	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1436000	USD
CY2020Q2	ekso	Adjustments To Additional Paid In Capital Warrant Issuance AdjustmentsToAdditionalPaidInCapitalWarrantIssuance	2322000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	508000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-193000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-28000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	2452000	USD
CY2020Q3	ekso	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	5875000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	55000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	191000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	636000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	517000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-415000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	8401000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2728000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6551000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7305000	USD
CY2019Q1	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	22000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	148000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	4534000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3066000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2393000	USD
CY2019Q2	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	173000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	919000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	557000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-106000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	5404000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	206000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	487000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	324000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	6421000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11849000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9411000	USD
	us-gaap	Depreciation Depreciation	465000	USD
	us-gaap	Depreciation Depreciation	519000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	101000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	29000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	43000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	63000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	189000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-1579000	USD
	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	6045000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	329000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	706000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1612000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1680000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	27000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	56000	USD
	ekso	Gain Loss On Modification Of Operating Lease Liabilities GainLossOnModificationOfOperatingLeaseLiabilities	-38000	USD
	ekso	Gain Loss On Modification Of Operating Lease Liabilities GainLossOnModificationOfOperatingLeaseLiabilities	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-66000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	ekso	Common Stock Contribution CommonStockContribution	155000	USD
	ekso	Common Stock Contribution CommonStockContribution	113000	USD
	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	424000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-90000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1772000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-409000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-384000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-715000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1608000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-368000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-195000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-169000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-95000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-185000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-23000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	647000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7015000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14277000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	60000	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7082000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16325000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1278000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1783000	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1512000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	3078000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3334000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	228000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10704000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14770000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-12000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-30000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3677000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	403000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10872000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7655000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14549000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8058000	USD
	us-gaap	Interest Paid Net InterestPaidNet	86000	USD
	us-gaap	Interest Paid Net InterestPaidNet	255000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000	USD
	ekso	Operating Leases Right Of Use Asset Initial Recognition OperatingLeasesRightOfUseAssetInitialRecognition	0	USD
	ekso	Operating Leases Right Of Use Asset Initial Recognition OperatingLeasesRightOfUseAssetInitialRecognition	1454000	USD
	ekso	Operating Leases Liability Initial Recognition OperatingLeasesLiabilityInitialRecognition	0	USD
	ekso	Operating Leases Liability Initial Recognition OperatingLeasesLiabilityInitialRecognition	1498000	USD
	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	160000	USD
	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	195000	USD
	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	155000	USD
	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	191000	USD
	us-gaap	Stock Issued1 StockIssued1	50000	USD
	us-gaap	Stock Issued1 StockIssued1	919000	USD
	ekso	Sales Earnout SalesEarnout	0	USD
	ekso	Sales Earnout SalesEarnout	22000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195127000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7015000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14549000	USD
	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.35
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3334000	USD
CY2020Q3	ekso	Debt Covenant Covenant Compliance Unrestricted Cash DebtCovenantCovenantComplianceUnrestrictedCash	2000000	USD
	ekso	Unrestricted Cash UnrestrictedCash	12549000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue and the deferral of the associated costs, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information, including the potential future effects of COVID-19. Actual results could differ from those estimates. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.</span></div>
CY2019Q1	us-gaap	Grants Receivable GrantsReceivable	1500000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers, most of which are hospitals or other large nationally recognizable institutions, in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of September 30, 2020 and December 31, 2019.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the Company had two customers with an accounts receivable balance totaling 10% or more of the Company’s total accounts receivable (10% and 15%), as compared with one customer at December 31, 2019 (11%).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, the Company had one customer with sales of 10% or more of the Company’s total revenue (13%), as compared with one customer in the three months ended September 30, 2019 (12%).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company had no customers with sales of 10% or more of the Company’s total revenue, as compared with one customer in the nine months ended September 30, 2019 (19%).</span></div>
CY2020Q2	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.35
	us-gaap	Restructuring Charges RestructuringCharges	244000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	189000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	189000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	189000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	0	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2208000	USD
CY2020Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2020Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2020000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	29000	USD
CY2020Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	160000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	252000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	2180000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	2489000	USD
CY2020Q3	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2823000	USD
CY2019Q4	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2837000	USD
CY2020Q3	ekso	Deferred Royalties DeferredRoyalties	282000	USD
CY2019Q4	ekso	Deferred Royalties DeferredRoyalties	290000	USD
CY2020Q3	us-gaap	Deferred Revenue Leases Net DeferredRevenueLeasesNet	146000	USD
CY2019Q4	us-gaap	Deferred Revenue Leases Net DeferredRevenueLeasesNet	131000	USD
CY2020Q3	ekso	Contract With Customers Liability Customer Deposits And Advances ContractWithCustomersLiabilityCustomerDepositsAndAdvances	7000	USD
CY2019Q4	ekso	Contract With Customers Liability Customer Deposits And Advances ContractWithCustomersLiabilityCustomerDepositsAndAdvances	23000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3258000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3281000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1448000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1492000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1810000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1789000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3281000	USD
	ekso	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	1256000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1279000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3258000	USD
CY2020Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3258000	USD
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	507000	USD
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1244000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4450000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5208000	USD
CY2020Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1507000	USD
CY2020Q3	ekso	Contract With Customer Liability Non Cancellable Backlog ContractWithCustomerLiabilityNonCancellableBacklog	504000	USD
CY2020Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2897000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6628000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3319000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10197000	USD
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1162000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1098000	USD
CY2020Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	206000	USD
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	285000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	300000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1566000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1683000	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1512000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14549000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	235000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	854000	USD
CY2020Q3	ekso	Long Term Debt Maturities Repayments Of Principal Remainder To Two Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderToTwoYear	0	USD
CY2020Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2000000	USD
CY2020Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2000000	USD
CY2020Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	7000	USD
CY2020Q3	us-gaap	Long Term Debt LongTermDebt	1993000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	26000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	593000	USD
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	75000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	779000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	406000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	405000	USD
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8316000	shares
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	134000	USD
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8316000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	373000	USD
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	779000	USD
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M8D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	132000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	404000	USD
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1178000	shares
	ekso	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	996000	shares
	ekso	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	723000	shares
	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	19000	shares
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1432000	shares
	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	517000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	487000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1612000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1680000	USD
CY2020Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2020Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2020Q3	us-gaap	Contractual Obligation ContractualObligation	302000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2452000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	206000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11849000	USD
	us-gaap	Dilutive Securities DilutiveSecurities	-294000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9411000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8236000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4996000	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9411000	USD
CY2020Q3	us-gaap	Dilutive Securities DilutiveSecurities	-2545000	USD
CY2019Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-93000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	206000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-12143000	USD
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6772000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4684000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	143000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	57000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8379000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4997000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6829000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4684000	shares
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.75
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.78
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	976000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1427000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	975000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1946000	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2897000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1084000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	1813000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3319000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1569000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	1750000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6628000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2919000	USD
	us-gaap	Gross Profit GrossProfit	3709000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10197000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5288000	USD
	us-gaap	Gross Profit GrossProfit	4909000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2897000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3319000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6628000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10197000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	45000	USD

Files In Submission

Name	View Source	Status
0001549084-20-000041-index-headers.html	Edgar Link	pending
0001549084-20-000041-index.html	Edgar Link	pending
0001549084-20-000041.txt	Edgar Link	pending
0001549084-20-000041-xbrl.zip	Edgar Link	pending
ekso-20200930.htm	Edgar Link	pending
ekso-20200930.xsd	Edgar Link	pending
ekso-20200930_cal.xml	Edgar Link	unprocessable
ekso-20200930_def.xml	Edgar Link	unprocessable
ekso-20200930_htm.xml	Edgar Link	completed
ekso-20200930_lab.xml	Edgar Link	unprocessable
ekso-20200930_pre.xml	Edgar Link	unprocessable
ekso-9302020xex311.htm	Edgar Link	pending
ekso-9302020xex312.htm	Edgar Link	pending
ekso-9302020xex321.htm	Edgar Link	pending
ekso-9302020xex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2020 Q4 Form 10-Q Financial Statement

#000154908420000041 Filed on October 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2020 Q4 Form 10-Q Financial Statement

#000154908420000041 Filed on October 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso